Mirum Pharmaceuticals, Inc. Earnings Per Share (Basic)
Mirum Pharmaceuticals, Inc. (MIRM) reported Earnings Per Share (Basic) of -$1.06 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$1.06.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$13.43.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was $0.06.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$0.12.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$0.47.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$1.85.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$4.00.
- Mirum Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$4.01.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.06 10-Q · filed 2026-08-05 | -$14.03 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$13.43 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$0.47 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $0.06 10-Q · filed 2025-11-04 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.35 10-Q · filed 2025-11-04 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.12 10-Q · filed 2026-08-05 | -$0.42 10-Q · filed 2026-08-05 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.30 10-Q · filed 2026-05-06 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-05-06 | |
| 2024-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-02-25 | -$1.85 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$0.30 10-Q · filed 2025-11-04 | -$1.36 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | -$0.52 10-Q · filed 2025-08-06 | -$1.06 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$0.54 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$4.00 10-K · filed 2026-02-25 | |||
| 2023-09-30 | -$0.57 10-Q · filed 2024-11-12 | -$3.28 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$1.94 10-Q · filed 2024-08-07 | -$2.75 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$0.80 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$0.99 derived: net income ÷ weighted average shares · filed 2025-02-26 | -$2.01 derived: net income ÷ weighted average shares · filed 2025-02-26 | -$2.86 derived: net income ÷ weighted average shares · filed 2025-02-26 | -$4.01 10-K · filed 2025-02-26 |
| 2022-09-30 | -$1.02 10-Q · filed 2023-11-02 | -$1.87 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$3.03 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$0.84 10-Q · filed 2023-08-07 | -$2.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$1.17 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$2.77 10-K · filed 2024-03-15 | |||
| 2021-09-30 | -$1.55 10-Q · filed 2022-11-09 | -$4.68 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$1.45 10-Q · filed 2022-08-04 | -$3.13 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |